Research Topics
| P J NeumannSummaryAffiliation: Harvard University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Are methods for estimating QALYs in cost-effectiveness analyses improving?P J Neumann
Program on the Economic Evaluation of Medical Technology, Harvard School of Public Health, Boston, MA 02115, USA
Med Decis Making 17:402-8. 1997..The objectives of this study were to examine variations in the methods used by researchers to estimate QALYs in published cost-effectiveness analyses, and to investigate whether the methods have improved over time...- Measuring Alzheimer's disease progression with transition probabilities: estimates from CERADP J Neumann
Program on the Economic Evaluation of Medical Technology, Center for Risk Analysis, Harvard School of Public Health, Boston, MA 02115, USA
Neurology 57:957-64. 2001.... - Why don't Americans use cost-effectiveness analysis?Peter J Neumann
Program on the Economic Evaluation of Medical Technology, Center for Risk Analysis, Harvard School of Public Health, Boston, MA 02115, USA
Am J Manag Care 10:308-12. 2004..This paper examines the resistance to CEA in the United States and explores ways in which to advance the field... - Growth and quality of the cost-utility literature, 1976-2001Peter J Neumann
Program on the Economic Evaluation of Medical Technology, Center for Risk Analysis, Harvard School of Public Health, Boston, MA 02115, USA
Value Health 8:3-9. 2005..This study updates and expands our previous work, which examined CUAs through 1997... - Economic messages in prescription drug advertisements in medical journalsPeter J Neumann
Program on the Economic Evaluation of Medical Technology, Center for Risk Analysis Harvard School of Public Health, Boston, Massachusetts 02115, USA
Med Care 40:840-5. 2002..Our objectives were to examine how often prescription drug advertisements in leading medical journals contain economic messages, and to determine the types of promotional claims made and whether supporting evidence is provided... - Do drug formulary policies reflect evidence of value?Peter J Neumann
Department of Health Policy and Management and Center for Risk Analysis, Harvard School of Public Health, Boston, MA 02115, USA
Am J Manag Care 12:30-6. 2006..To investigate the extent to which preferred drug lists and tiered formularies reflect evidence of value, as measured in published cost-utility analyses (CUAs)... - Health utilities in Alzheimer's disease and implications for cost-effectiveness analysisPeter J Neumann
Department of Health Policy and Management and Center for Risk Analysis, Harvard School of Public Health, Boston, Massachusetts, USA
Pharmacoeconomics 23:537-41. 2005..The NICE assumption that they do not results in a difference in utilities between dependent and non-dependent AD individuals of only 0.06. This seems to be at the low end of what one would consider a reasonable estimate... - A comparison of HUI2 and HUI3 utility scores in Alzheimer's diseaseP J Neumann
Program on the Economic Evaluation of Medical Technology, Center for Risk Analysis, Harvard School of Public Health, Boston, Massachusetts 02115, USA
Med Decis Making 20:413-22. 2000..The authors compared HUI2 and HUI3 scores of patients with Alzheimer's disease (AD) and caregivers, and contrasted results of a cost-effectiveness analysis of new drugs for AD using the two systems... - Do HEDIS measures reflect cost-effective practices?Peter J Neumann
Program on the Economic Evaluation of Medical Technology, Center for Risk Analysis, Harvard School of Public Health, Boston, Massachusetts 02115, USA
Am J Prev Med 23:276-89. 2002..Our study objectives were to examine the cost-effectiveness evidence for the clinical practices underlying HEDIS 2000 measures and to develop a list of practices not reflected in HEDIS that have evidence of cost effectiveness... - Preference-based measures in economic evaluation in health careP J Neumann
Program on the Economic Evaluation of Medical Technology, Center for Risk Analysis, Harvard School of Public Health, Boston, Massachusetts 02115, USA
Annu Rev Public Health 21:587-611. 2000..Widespread acceptance of the methodology likely awaits more consensus on measurement techniques, as well as educational efforts in the public health and medical communities on the usefulness of the approach... - The quality of reporting in published cost-utility analyses, 1976-1997P J Neumann
Harvard School of Public Health, Boston, Massachusetts 02115, USA
Ann Intern Med 132:964-72. 2000..We examined quality of reporting by journal type and number of cost-utility analyses a journal has published... - Health utilities in Alzheimer's disease: a cross-sectional study of patients and caregiversP J Neumann
Program on the Economic Evaluation of Medical Technology, Center for Risk Analysis, Harvard School of Public Health, Boston, MA 02115, USA
Med Care 37:27-32. 1999.... - Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's diseaseP J Neumann
Program on the Economic Evaluation of Medical Technology, Center for Risk Analysis, Harvard School of Public Health, Boston, MA 02115, USA
Neurology 52:1138-45. 1999..To demonstrate the use of cost-effectiveness analysis to assess the economic impact of donepezil in the treatment of mild or moderate AD... - Medicare's national coverage decisions, 1999-2003: quality of evidence and review timesPeter J Neumann
Harvard School of Public Health in Boston, Massachusetts, USA
Health Aff (Millwood) 24:243-54. 2005..Decisions referred to the external Medicare Coverage Advisory Committee (MCAC) have averaged eight months longer than non-MCAC decisions... - Methods of cost-effectiveness analysis in the assessment of new drugs for Alzheimer's diseaseP J Neumann
Program on the Economic Evaluation of Medical Technology, Harvard School of Public Health, Boston, MA 02115, USA
Psychiatr Serv 48:1440-4. 1997.... - Can we better prioritize resources for cost-utility research?Peter J Neumann
Harvard School of Public Health, Boston, MA 02115, USA
Med Decis Making 25:429-36. 2005.... - Who gets chemotherapy for metastatic lung cancer?C C Earle
Center for Outcomes and Policy Research, Department of Adult Oncology Dana Farber Cancer Institute, Boston, MA 02115, USA
Chest 117:1239-46. 2000..To determine the prevalence and factors associated with chemotherapy use in elderly patients presenting with advanced lung cancer... - The association between caregiver burden and caregiver health-related quality of life in Alzheimer diseaseC M Bell
Program on the Economic Evaluation of Medical Technology, Center for Risk Analysis, Harvard School of Public Health, Boston, Massachusetts, USA
Alzheimer Dis Assoc Disord 15:129-36. 2001..The development of condition-specific preference-weighted instruments may provide the means to better estimate HRQOL in AD caregivers... - Modeling for health care and other policy decisions: uses, roles, and validityM C Weinstein
Program on the Economic Evaluation of Medical Technology, Harvard Center for Risk Analysis, Harvard School of Public Health, 718 Huntington Avenue, Boston, MA 02115, USA
Value Health 4:348-61. 2001..Implications for the implementation of Section 114 of the Food and Drug Administration Modernization Act (FDAMA) are derived from this framework... - An off-the-shelf help list: a comprehensive catalog of preference scores from published cost-utility analysesC M Bell
Program on the Economic Evaluation of Medical Technology, Harvard Center for Risk Analysis, Harvard School of Public Health, Boston, Massachusetts 02115, USA
Med Decis Making 21:288-94. 2001..hsph.harvard.edu/organizations/hcra/cuadatabase/ intro.html) may provide a useful reference tool for producers and consumers of CUAs but also underscores the methodologic variation and inconsistencies present in the field... - Systematic overview of cost-utility assessments in oncologyC C Earle
Center for Outcomes and Policy Research, Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
J Clin Oncol 18:3302-17. 2000..We critically reviewed the CUA literature and its role in informing clinical oncology practice, research priorities, and policy... 
Measuring the value of public health systems: the disconnect between health economists and public health practitionersPeter J Neumann
Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA 02111, USA
Am J Public Health 98:2173-80. 2008..g., social justice and reassurance value). Academic researchers evaluating the economics of public health investments should increase focus on the working needs of public health professionals...- Cost-effectiveness of migraine prevention: the case of topiramate in the UKJ S Brown
Harvard Medical School/Harvard Pilgrim Health Care, Department of Ambulatory Care and Prevention, Boston, MA, USA
Cephalalgia 26:1473-82. 2006..This analysis suggests that topiramate is a cost-effective treatment for migraine prevention compared with no preventive treatment... - Do oncologists believe new cancer drugs offer good value?Eric Nadler
Dana Faber Cancer Institute Harvard Medical School, Boston, MA, USA
Oncologist 11:90-5. 2006..Oncologists play a pivotal role in treatment decisions, yet it is unclear whether they perceive high-cost new treatments to offer good value or how therapeutic costs factor into their treatment recommendations... 
Costing and perspective in published cost-effectiveness analysisPeter J Neumann
Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, Massachusetts 02111, USA
Med Care 47:S28-32. 2009..Questions linger about what cost components to include under a "societal" perspective, as well as how to value resources...- Evidence-based and value-based formulary guidelinesPeter J Neumann
Program on the Economic Evaluation of Medical Technology, Center for Risk Analysis, Harvard School of Public Health, Boston, Massachusetts, USA
Health Aff (Millwood) 23:124-34. 2004..This paper describes the guidelines, reviews progress to date, and analyzes several critical issues for the future... - A bibliometric review of cost-effectiveness analyses in the economic and medical literature: 1976-2006Dan Greenberg
Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts, USA
Med Decis Making 30:320-7. 2010..Despite the proliferation of CEA research, there has been no detailed study focusing on the bibliometric properties of this literature... - Quality of clinical and economic evidence in dossier formulary submissionsFernando Colmenero
Harvard School of Public Health, Boston, MA, USA
Am J Manag Care 13:401-7. 2007..To investigate the quality and completeness of clinical and economic data in dossiers submitted by drug companies to a health plan using Academy of Managed Care Pharmacy guidelines (the Format) for formulary submissions... - Effectiveness of chemotherapy for advanced lung cancer in the elderly: instrumental variable and propensity analysisC C Earle
Center for Outcomes and Policy Research, Dana Farber Cancer Institute, Boston, MA 02115, USA
J Clin Oncol 19:1064-70. 2001..To compare the effectiveness of chemotherapy given to elderly patients in routine practice for stage IV non-small-cell lung cancer (NSCLC) with the efficacy observed in randomized trials... - Impact of referral patterns on the use of chemotherapy for lung cancerCraig C Earle
Center for Outcomes and Policy Research, Dana Farber Cancer Center, Boston, MA 02115, USA
J Clin Oncol 20:1786-92. 2002..To determine the extent to which unexplained variation in the use of chemotherapy for advanced lung cancer is due to access to oncologists' services as opposed to treatment decisions made after seeing an oncologist... - Cost-effective diagnostic cardiovascular imaging: when does it provide good value for the money?Hansel J Otero
Department of Radiology, Tufts Medical Center and Tufts University School of Medicine, Boston, MA 02111, USA
Int J Cardiovasc Imaging 26:605-12. 2010..The studies available have, in general, favorable cost-effectiveness profiles with major determinants relating to being compared against observation, medical or no intervention instead of other imaging tests... - Cost-utility analyses in orthopaedic surgeryCarmen A Brauer
Harvard Center for Risk Analysis, Harvard School of Public Health, 718 Huntington Avenue, Boston, MA 02115, USA
J Bone Joint Surg Am 87:1253-9. 2005..We critically reviewed the literature on orthopaedic cost-utility analysis to determine which subspecialty areas are represented, the cost-utility ratios that have been utilized, and the quality of the present literature... - The arrival of economic evidence in managed care formulary decisions: the unsolicited request processPeter J Neumann
Department of Policy and Decision Sciences, Harvard School of Public Health, Boston, Massachusetts 02115, USA
Med Care 43:27-32. 2005..This article describes the unsolicited request process and its potential impact on the use of economic evidence in formulary decisions... - Long-term persistence in use of statin therapy in elderly patientsJoshua S Benner
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 221 Longwood Ave, Suite 341, Boston, MA 02115, USA
JAMA 288:455-61. 2002.... - Trends in the measurement of health utilities in published cost-utility analysesCarmen A Brauer
Harvard Center for Risk Analysis, Harvard School of Public Health, Boston, MA, USA
Value Health 9:213-8. 2006..tufts-nemc.org/cearegistry; previously at http://www.hsph.harvard.edu/cearegistry), and documents recent changes in methods used for utility weight elicitation... - Medicare and cost-effectiveness analysisPeter J Neumann
Department of Health Policy and Management and the Center for Risk Analysis, Harvard School of Public Health, Boston, USA
N Engl J Med 353:1516-22. 2005 - The adoption of cost-effectiveness acceptability curves in cost-utility analysesLisa M Meckley
Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts 02111, USA
Med Decis Making 30:314-9. 2010..g., life-years or quality-adjusted life-years gained)... - Direct-to-consumer advertising and shared liability for pharmaceutical manufacturersMichelle M Mello
Department of Health Policy and Management, Harvard School of Public Health, 677 Huntington Ave, Boston, Mass 02115, USA
JAMA 289:477-81. 2003 - Delays in publication of cost utility analyses conducted alongside clinical trials: registry analysisDan Greenberg
Harvard Center for Risk Analysis, Department of Health Policy and Management, Harvard School of Public Health, 718 Huntington Avenue, Boston, MA 02115, USA
BMJ 328:1536-7. 2004 - When does quality-adjusting life-years matter in cost-effectiveness analysis?Richard H Chapman
Program on the Economic Evaluation of Medical Technology, Harvard Center for Risk Analysis, Harvard School of Public Health, Boston, Massachusetts 02115, USA
Health Econ 13:429-36. 2004.... - The impact of risk information on patients' willingness to pay for autologous blood donationS J Lee
Division of Hematology Oncology, Brigham and Women s Hospital, Boston, MA, USA
Med Care 36:1162-73. 1998.... - Emerging lessons from the drug effectiveness review projectPeter J Neumann
Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts New England Medical Center, Boston, Massachusetts, USA
Health Aff (Millwood) 25:W262-71. 2006.... - Cost-effectiveness of PET in the diagnosis of Alzheimer diseasePamela M McMahon
Institute for Technology Assessment, Massachusetts General Hospital, Zero Emerson Place, Suite 2H, Boston, MA 02114, USA
Radiology 228:515-22. 2003..CONCLUSION: PET may have high diagnostic accuracy, but adding it to the standard diagnostic regimen at AD clinics would yield limited, if any, benefits at very high costs... - A strategic plan for integrating cost-effectiveness analysis into the US healthcare systemPeter J Neumann
Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, 800 Washington St, 063, Boston, MA 02111, USA
Am J Manag Care 14:185-8. 2008.... - Public attitudes about genetic testing for Alzheimer's diseaseP J Neumann
Program on the Economic Evaluation of Medical Technology at the Harvard School of Public Health, Boston, Massachusetts, USA
Health Aff (Millwood) 20:252-64. 2001..The results suggest that people value genetic testingfor personal and financial reasons, but they also underscore the need to counsel potential recipients carefully about the accuracy and implications of test information... - Economic evaluation in the US: what is the missing link?Peter J Neumann
Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Care Policy, Tufts New England Medical Center, Boston, Massachusetts, USA
Pharmacoeconomics 24:1163-8. 2006..However, a more likely outcome is the ongoing indirect use of cost-effectiveness information... - Medicare's national coverage decisions for technologies, 1999-2007Peter J Neumann
Institute for Clinical Research and Health Policy Studies, at Tufts Medical Center in Boston, Massachusetts, USA
Health Aff (Millwood) 27:1620-31. 2008.... - When is critical care medicine cost-effective? A systematic review of the cost-effectiveness literatureDaniel Talmor
Department of Anesthesia, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
Crit Care Med 34:2738-47. 2006..Cost-effectiveness analyses (CEAs) have become increasingly common to aid decisions about the allocation of scarce healthcare resources... - Decision analytic models for Alzheimer's disease: state of the art and future directionsJoshua T Cohen
Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts New England Medical Center, Boston, MA, USA
Alzheimers Dement 4:212-22. 2008.... - 30 years of pharmaceutical cost-utility analyses: growth, diversity and methodological improvementPeter J Neumann
The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts, USA
Pharmacoeconomics 27:861-72. 2009..The results highlight that there are many opportunities for efficient healthcare investment, among pharmaceutical and non-pharmaceutical interventions, just as there are many investments that are inefficient... - Valuing children's health: a comparison of cost-utility analyses for adult and paediatric health interventions in the USJoseph A Ladapo
Harvard Medical School and Harvard Graduate School of Arts and Sciences, Boston, Massachusetts, USA
Pharmacoeconomics 25:817-28. 2007.... - Quality-adjusted life years in cancer: pros, cons, and alternativesR M Woodward
Boston Health Economics, Inc, Waltham, MA 02451, USA
Eur J Cancer Care (Engl) 22:12-9. 2013..In this paper, we summarise the use of the quality-adjusted life years to assess the value of cancer care and suggest potential ways to improve upon value measurement in cancer coverage and reimbursement decisions... - FEV(1) is associated with risk of asthma attacks in a pediatric populationA L Fuhlbrigge
Channing Laboratory, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115-5805, USA
J Allergy Clin Immunol 107:61-7. 2001..CONCLUSION: The strong association between FEV(1)% and risk of asthma attack over the subsequent year supports an emphasis on objective measures of lung function in assessment of risk for adverse asthma outcomes... - Migraine frequency and health utilities: findings from a multisite surveyJeffrey S Brown
Department of Ambulatory Care and Prevention, Harvard Medical School Harvard Pilgrim Health Care, Boston, MA, USA
Value Health 11:315-21. 2008..Assess the relationship between migraine frequency and health utility... - Cross-national comparison of technology assessment processesAnna García-Altés
Harvard School of Public Health, Boston, Massachusetts 02115, USA
Int J Technol Assess Health Care 20:300-10. 2004..To compare methods and results among four health technology assessment organizations in different countries... - Does preventive care save money? Health economics and the presidential candidatesJoshua T Cohen
Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts New England Medical Center, Boston, USA
N Engl J Med 358:661-3. 2008 - When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncologyDan Greenberg
Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA 02111, USA
J Natl Cancer Inst 102:82-8. 2010..Because we found only modest improvement in the quality of studies, we suggest that journals provide specific guidance for reporting CUA and assure that authors adhere to guidelines for conducting and reporting economic evaluations... - FDA actions against misleading or unsubstantiated economic and quality-of-life promotional claims: an analysis of warning letters and notices of violationKate A Stewart
Program on the Economic Evaluation of Medical Technology, Center for Risk Analysis, Harvard School of Public Health, 7218 Huntington Avenue, Boston, MA 02115, USA
Value Health 5:390-7. 2002..More guidance may be needed to ensure appropriate use of these claims in drug promotions... - Low-value services in value-based insurance designPeter J Neumann
Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, MA 02111, USA
Am J Manag Care 16:280-6. 2010..To identify potentially low-value services for inclusion in value-based insurance design (VBID) programs and to discuss challenges involved in incorporating such information... - Twenty years of cost-effectiveness analysis in medical imaging: are we improving?Hansel J Otero
Department of Radiology, Brigham and Women s Hospital, Harvard Medical School, 75 Francis St, Boston, MA 02115, USA
Radiology 249:917-25. 2008..S. Panel on Cost-effectiveness in Health and Medicine recommendations affected CEA studies in which imaging technologies were evaluated... - Willingness to pay for avoiding coronary restenosis and repeat revascularization: results from a contingent valuation studyDan Greenberg
Harvard Clinical Research Institute, Boston, MA, USA
Health Policy 70:207-16. 2004..These findings may have important implications for emerging technologies such as drug-eluting stents... - Quality-adjusted life years: how useful in medico economic studiesCarmen A Brauer
Program on the Economic Evaluation of Medical Technology, Harvard Center for Risk Analysis, Harvard School of Public Health, Boston, MA, USA
Fundam Clin Pharmacol 19:603-7. 2005..The purpose of this paper is to highlight some of the issues surrounding the use of QALYs and to encourage researchers to present their methodology in a clear and transparent way... - Key principles for the improved conduct of health technology assessments for resource allocation decisionsMichael F Drummond
Centre for Health Economics, University of York, Heslington, York, UK
Int J Technol Assess Health Care 24:244-58; discussion 362-8. 2008..The principles are organized into four sections: (i) "Structure" of HTA programs; (ii) "Methods" of HTA; (iii) "Processes for Conduct" of HTA; and (iv) "Use of HTAs in Decision Making.".. - When is evidence sufficient?Karl Claxton
University of York, United Kingdom
Health Aff (Millwood) 24:93-101. 2005..Value-of-information analysis, a related methodology, helps to determine whether it is worthwhile to collect additional information as well as the type of research that would be most helpful... - Bias in published cost effectiveness studies: systematic reviewChaim M Bell
St Michael s Hospital, Toronto, Ontario, Canada M5B 1W8
BMJ 332:699-703. 2006.... - Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force reportLouis P Garrison
University of Washington, Seattle, WA 98195, USA
Value Health 10:326-35. 2007.... - Budget impact analyses get some respectPeter J Neumann
Value Health 10:324-5. 2007 - What affects the quality of economic analysis for life-saving investments?Robert W Hahn
AEI Brookings Joint Center for Regulatory Studies, Washington, DC 20036, USA
Risk Anal 26:641-55. 2006..Somewhat surprisingly, a study's funding source and whether it is affiliated with industry are not significantly correlated with the quality index. Finally, neither time nor the panel guidelines had an impact on the index... - The economic burden of intracerebral hemorrhage: evidence from managed careMason W Russell
Boston Health Economics, Waltham, Massachusetts 02451, USA
Manag Care Interface 19:24-8, 34. 2006..Treatment costs for ICH to private payers appear to be considerable and may reflect a sizable long-term financial burden to U.S. health plans... - Diffusion of published cost-utility analyses in the field of health policy and practiceSeema S Sonnad
Department of Surgery, University of Pennsylvania, Philadelphia, Pennsylvania 19104 4283, USA
Int J Technol Assess Health Care 21:399-402. 2005..The diffusion of cost-utility analyses (CUAs) through the medical literature was examined, documenting visible patterns and determining how they correspond with expectations about the diffusion of process innovations... - Challenges ahead for federal technology assessmentPeter J Neumann
Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts New England Medical Center, MA, USA
Health Aff (Millwood) 26:w150-2. 2007..Efforts are also needed to prioritize research, to communicate it to decision-makers, to involve stakeholders in the process, and to include cost-effectiveness information... - Biotechnology and Medicare's new technology policy: lessons from three case studiesPatricia Seliger Keenan
Division of Health Policy and Administration, Department of Epidemiology and Public Health, Yale University School of Medicine in New Haven, Connecticut, USA
Health Aff (Millwood) 25:1260-9. 2006..The cases suggest Medicare's ongoing challenge to balance access considerations, the role and strength of evidence, and cost consequences of new treatments... - A synthesis of cost-utility analysis literature in infectious diseasePatricia W Stone
Columbia University School of Nursing, New York, NY 10032, USA
Lancet Infect Dis 5:383-91. 2005..The results of cost-utility analyses have important implications for the development of clinical guidelines and resource allocation decisions. More trained investigators and better peer-review processes are needed... - Trends in cost effectiveness analyses in orthopaedic surgeryCarmen A Brauer
Department of Orthopaedic Surgery, British Columbia Children s Hospital, Vancouver, BC, Canada
Clin Orthop Relat Res 457:42-8. 2007.... - The impact of Medicare modernization on coverage policy: recommendations for reformSusan Bartlett Foote
Division of Health Services Research and Policy, School of Public Health, University of Minnesota, Minneapolis, Minn 55455, USA
Am J Manag Care 11:140-2. 2005 - Prevalence and impact of medical comorbidity in Alzheimer's diseaseP Murali Doraiswamy
Department of Psychiatry, Duke University Medical Center, Durham, North Carolina 27710, USA
J Gerontol A Biol Sci Med Sci 57:M173-7. 2002..We examined the prevalence of comorbid medical illnesses in Alzheimer's disease (AD) patients at different severity levels. We also examined the effect of cumulative medical comorbidity on cognition and function... - Economic burden of pertussis and the impact of immunizationJ Jaime Caro
Caro Research Institute, Concord, MA 01742, USA
Pediatr Infect Dis J 24:S48-54. 2005..Despite the existing gaps in data, further research using the most current data should facilitate decisions on new vaccination strategies by describing conditions for favorable results and quantifying the margin of uncertainty... - Quality of abstracts of papers reporting original cost-effectiveness analysesAllison B Rosen
Division of General Medicine, University of Michigan Health Systems, Department of Health Management and Policy, University of Michigan School of Public Health, Ann Arbor Veterans Affairs Medical Center, Ann Arbor, MI 48109, USA
Med Decis Making 25:424-8. 2005..The authors examined the extent to which abstracts of published CEAs include key data elements (intervention, comparator, target population, study perspective) and assessed the effect of journal characteristics on reporting quality... - Development and validation of a grading system for the quality of cost-effectiveness studiesChiun Fang Chiou
Zynx Health Inc, Cerner Corporation, Beverly Hills, California 90212, USA
Med Care 41:32-44. 2003..To provide a practical quantitative tool for appraising the quality of cost-effectiveness (CE) studies... - Examining the value and quality of health economic analyses: implications of utilizing the QHESJoshua J Ofman
Zynx Health Inc, 9100 Wilshire Blvd, East Tower, Suite 655, Beverly Hills, CA 90212, USA
J Manag Care Pharm 9:53-61. 2003..To examine the increasing use of health economic studies and practical implications of evaluating their quality utilizing the Quality of Health Economic Studies (QHES) instrument... - Cost-effectiveness of topiramate in migraine prevention: results from a pharmacoeconomic model of topiramate treatmentJeffrey S Brown
Boston Health Economics, Inc, Waltham, MA 02451, USA
Headache 45:1012-22. 2005..However, results from our model suggest that the use of TPM in prevention of migraine may offer reasonable value for money relative to many well-accepted medical interventions... - How often do sensitivity analyses for economic parameters change cost-utility analysis conclusions?Bruce R Schackman
Division of Outcomes and Effectiveness Research, Department of Public Health, Weill Medical College of Cornell University, New York 10021, USA
Pharmacoeconomics 22:293-300. 2004..Sensitivity analyses for health-related QOL (HR-QOL), cost and discount rate economic parameters are of particular interest because they measure the effects of methodological and estimation uncertainties...
Research Grants
- A Comprehensive Database of Cost-Effectiveness AnalysesPeter Neumann; Fiscal Year: 2003..The web-based data should also understand the needs of different scientists to be understood and policymakers, and bridges to be built across disparate communities. ..